Edition:
India

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

55.20USD
17 Nov 2017
Change (% chg)

$0.03 (+0.05%)
Prev Close
$55.17
Open
$55.00
Day's High
$55.43
Day's Low
$54.76
Volume
3,377,173
Avg. Vol
2,954,693
52-wk High
$66.80
52-wk Low
$54.41

Latest Key Developments (Source: Significant Developments)

Cue Biopharma announces collaboration with Merck
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Cue Biopharma:‍Cue Biopharma says a strategic research collaboration and license agreement with Merck.Cue Biologics platform will be leveraged to develop biologics engineered to selectively modulate disease-relevant T cell subsets​.Says specific financial arrangements are not being disclosed​.Says will receive an up-front payment​.Eligible to earn up to $374 million in research, regulatory & commercial milestone payments in addition to tiered royalties on sales​.  Full Article

Merck reports 6.5 pct passive stake in Spero Therapeutics as of Nov 6
Thursday, 16 Nov 2017 

Nov 15 (Reuters) - Merck & Co Inc :Merck & Co reports 6.5 percent passive stake in Spero Therapeutics Inc as of Nov 6 - SEC Filing​.  Full Article

Merck reports final results of any and all tender offers
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Merck & Co Inc ::Merck announces final results of any and all tender offers.Merck & Co Inc - ‍offers expired at 5:00 p.m., New York City time, on Nov. 13, 2017​.Merck - amount of notes tendered & accepted for purchase was about $584.7 million, exclusive of notes tendered pursuant to guaranteed delivery procedures​.  Full Article

Merck announces pricing of any and all tender offers
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Merck & Co Inc ::Merck announces pricing of any and all tender offers.Says ‍as of date of offers, aggregate outstanding principal amount of notes was about $2.95 billion​.Says ‍offers are scheduled to expire at 5:00 p.m., New York City Time, on Nov.13, 2017​.  Full Article

Array Biopharma reports initial results from novel immunotherapy combination at SITC annual meeting
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Array Biopharma Inc :Array biopharma reports initial results from novel immunotherapy combination at the Society For Immunotherapy Of Cancer (SITC) 32nd annual meeting.Array Biopharma Inc - ‍plans to expand ongoing phase 2 CSF1R + PD1 combination study into other tumor types including pancreatic cancer​.  Full Article

Merck receives FDA approval of Prevymis for prevention of CMV infection in allogeneic stem cell transplant patients
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Merck & Co Inc :Merck receives FDA approval of Prevymis (letermovir) for prevention of cytomegalovirus (CMV) infection and disease in adult allogeneic stem cell transplant patients.Merck & Co Inc - ‍Prevymis is expected to be available in december​.Merck & Co Inc - ‍list price (wholesaler acquisition cost) per day for Prevymis tablets is $195.00 and for Prevymis injection is $270.00​.  Full Article

Merck & Co updates on investigation of co's Italian unit
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Merck & Co Inc :Merck & Co Inc says in July 2017, co learned that the prosecution office of Milan, Italy is investigating certain interactions - SEC filing.Merck & Co says the interactions were between co’s Italian subsidiary, certain employees of the subsidiary and certain Italian healthcare providers.Merck says it understands that this is part of a larger investigation involving engagements between various healthcare companies and certain healthcare providers.Merck & Co says it is cooperating with the investigation.  Full Article

Merck announces any and all tender offers
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Merck & Co Inc :Merck announces any and all tender offers.Merck & Co Inc - ‍Offers are being made upon, and are subject to, terms and conditions set forth in offer to purchase, dated Nov. 6, 2017​.Merck & Co Inc - ‍Offers will expire at 5:00 p.m. on Nov. 13, 2017​.  Full Article

FDA approves roll-over combination study of BriaVax with pembrolizumab
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Briacell Therapeutics Corp :FDA approves the roll-over combination study with checkpoint inhibitor immunotherapies to allow continued access to BriaVax in patients with advanced breast cancer.Briacell Therapeutics - ‍FDA approved roll-over combination study of BriaVax with pembrolizumab or ipilimumab.Briacell- ‍FDA approved roll-over combination study for patients previously treated with BriaVax from Phase I/IIa clinical trial in advanced breast cancer​.  Full Article

Merck withdraws European application for Keytruda
Saturday, 28 Oct 2017 

Oct 27 (Reuters) - Merck & Co Inc ::Merck provides update on European application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin for first-line treatment of nonsquamous non-small cell lung cancer (NSCLC).Withdrawn European application for Keytruda in combination with pemetrexed, carboplatin as first-line treatment for metastatic nonsquamous NSCLC.Company is confident in clinical data from Keynote-021, Cohort G​.  Full Article

BRIEF-Cue Biopharma announces collaboration with Merck

* ‍Cue Biopharma says a strategic research collaboration and license agreement with Merck